|
1
|
Stintzing S, Modest DP, Rossius L, Lerch
MM, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U,
Al-Batran SE, Heintges T, et al: FOLFIRI plus cetuximab versus
FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3):
A post-hoc analysis of tumour dynamics in the final RAS wild-type
subgroup of this randomised open-label phase 3 trial. Lancet Oncol.
17:1426–1434. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Grothey A, Sargent D, Goldberg RM and
Schmoll HJ: Survival of patients with advanced colorectal cancer
improves with the availability of fluorouracil-leucovorin,
irinotecan, and oxaliplatin in the course of treatment. J Clin
Oncol. 22:1209–1214. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bennouna J, Sastre J, Arnold D, Österlund
P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C,
et al: Continuation of bevacizumab after first progression in
metastatic colorectal cancer (ML18147): A randomised phase 3 trial.
Lancet Oncol. 14:29–37. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jonker DJ, O'Callaghan CJ, Karapetis CS,
Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, et
al: Cetuximab for the treatment of colorectal cancer. N Engl J Med.
357:2040–2048. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cunningham D, Humblet Y, Siena S, Khayat
D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype
C, et al: Cetuximab monotherapy and cetuximab plus irinotecan in
irinotecan-refractory metastatic colorectal cancer. N Engl J Med.
351:337–345. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Naruse I, Ohmori T, Ao Y, Fukumoto H,
Kuroki T, Mori M, Saijo N and Nishio K: Antitumor activity of the
selective epidermal growth factor receptor-tyrosine kinase
inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing
multidrug-resistant cell line in vitro and in vivo. Int J Cancer.
98:310–315. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sclabas GM, Fujioka S, Schmidt C, Fan Z,
Evans DB and Chiao PJ: Restoring apoptosis in pancreatic cancer
cells by targeting the nuclear factor-kappaB signaling pathway with
the anti-epidermal growth factor antibody IMC-C225. J Gastrointest
Surg. 7:37–43. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huang SM and Harari PM: Modulation of
radiation response after epidermal growth factor receptor blockade
in squamous cell carcinomas: Inhibition of damage repair, cell
cycle kinetics, and tumor angiogenesis. Clin Cancer Res.
6:2166–2174. 2000.PubMed/NCBI
|
|
9
|
Van Emburgh BO, Sartore-Bianchi A, Di
Nicolantonio F, Siena S and Bardelli A: Acquired resistance to
EGFR-targeted therapies in colorectal cancer. Mol Oncol.
8:1084–1094. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Diehl F, Schmidt K, Choti MA, Romans K,
Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, et al:
Circulating mutant DNA to assess tumor dynamics. Nat Med.
14:985–990. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Diaz LA Jr, Williams RT, Wu J, Kinde I,
Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, et al:
The molecular evolution of acquired resistance to targeted EGFR
blockade in colorectal cancers. Nature. 486:537–540. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer Res.
45:228–247. 2009. View Article : Google Scholar
|
|
13
|
Nagasaka T, Tanaka N, Cullings HM, Sun DS,
Sasamoto H, Uchida T, Koi M, Nishida N, Naomoto Y, Boland CR, et
al: Analysis of fecal DNA methylation to detect gastrointestinal
neoplasia. J Natl Cancer Inst. 101:1244–1258. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Peeters M, Oliner KS, Price TJ, Cervantes
A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, et
al: Analysis of KRAS/NRAS mutations in a phase III study of
panitumumab with FOLFIRI compared with FOLFIRI alone as second-line
treatment for metastatic colorectal cancer. Clin Cancer Res.
21:5469–5479. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sidhu R, Rong A and Dahlberg S: Evaluation
of progression-free survival as a surrogate endpoint for survival
in chemotherapy and targeted agent metastatic colorectal cancer
trials. Clin Cancer Res. 19:969–976. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shi Q, de Gramont A, Grothey A, Zalcberg
J, Chibaudel B, Schmoll HJ, Seymour MT, Adams R, Saltz L, Goldberg
RM, et al: Individual patient data analysis of progression-free
survival versus overall survival as a first-line end point for
metastatic colorectal cancer in modern randomized trials: Findings
from the analysis and research in cancers of the digestive system
database. J Clin Oncol. 33:22–28. 2015. View Article : Google Scholar : PubMed/NCBI
|
